Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057743 · ClinicalTrials.gov registry record
Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- 4
- Enrollment target
NCT03057743: Clinical Trial study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT03057743 is a clinical trial that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03057743 was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Pilot study using \[18F\]ISO-1 PET/CT to image sigma-2 receptor binding in metastatic breast cancer. Correlate baseline uptake and change in uptake after therapy with time to progression and standard and experimental pathology assays of biopsy or surgical tissue. The target population is up to 30 adult patients at least 18 years, with at least one site of disease outside the liver by at least one type of standard imaging.
Interventions
- DEVICE Positron emission tomography (PET/CT) imaging
- DEVICE radiotracer [18F]ISO-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-04-05 |
| Est. Completion | 2021-11-01 |
Why NCT03057743 stopped before completion
NCT03057743 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Positron emission tomography (PET/CT) imaging is the first listed.
NCT03057743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03057743 about?
NCT03057743 is a clinical study titled "Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer". Pilot study using \[18F\]ISO-1 PET/CT to image sigma-2 receptor binding in metastatic breast cancer. Correlate baseline uptake and change in uptake after therapy with time to progression and standard and experimental pathology assays of biopsy or surgical tissue. The target population is up to 30 ad...
What is the current status of trial NCT03057743?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2016-04-05. Estimated completion is 2021-11-01.
What interventions are being tested in trial NCT03057743?
The interventions under investigation include: Positron emission tomography (PET/CT) imaging (DEVICE), radiotracer [18F]ISO-1 (DEVICE).
Who is sponsoring clinical trial NCT03057743?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI